Can Cannabinoids Slow Ageing? Early Lab Evidence Is Intriguing, But Human Proof Remains Absent

A 2024 narrative review published in GeroScience maps preclinical findings on CBD and the endocannabinoid system across model organisms, with nematode studies forming the core evidence base, while candidly acknowledging the long and uncertain road to human translation.

Why This Matters

Ageing is the single largest risk factor for the chronic diseases that dominate modern healthcare, and identifying interventions that extend not just lifespan but healthspan is a pressing scientific priority. Cannabinoids, particularly CBD, are already widely used by older adults for pain, sleep, and general wellness, often with implicit or explicit anti-ageing claims attached. That widespread consumer adoption makes it especially important to examine what the underlying biology actually shows and, just as critically, where the evidence stops. This review arrives at a moment when the gap between public enthusiasm and scientific proof is unusually wide.

Clinical Summary

The endocannabinoid system, a network of receptors, endogenous ligands, and metabolic enzymes distributed throughout the central nervous system and peripheral tissues, undergoes measurable changes with age. Expression of CB1 receptors declines in the human prefrontal cortex, and enzymes responsible for synthesizing endocannabinoids such as 2-arachidonoylglycerol decrease in aged animals. Against this backdrop, a 2024 narrative review by researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, published in GeroScience, examines whether exogenous cannabinoids, especially CBD, can modulate ageing processes. The mechanistic rationale centres on two pathways: autophagy induction, through which damaged cellular components are cleared, and activation of antioxidative defence systems that counteract the oxidative stress known to accumulate with age.

The strongest evidence comes from studies in Caenorhabditis elegans, a nematode worm with well-characterized ageing genetics and a short lifespan amenable to intervention studies. In these models, CBD extends lifespan and improves healthspan parameters, with supporting mechanistic data linking the effect to autophagy and redox pathways. Complementary findings in Drosophila and zebrafish exist but are less developed. In rodents, genetic deletion of CB1 receptors accelerates age-related cognitive decline, suggesting endogenous cannabinoid tone has a protective role, but this is correlational rather than interventional. No controlled human trials examining cannabinoid effects on lifespan or healthspan are included or referenced. The authors explicitly identify translational mammalian studies and broader investigation of minor cannabinoids as the critical unmet research priorities before any clinical inference is appropriate.

Dr. Caplan’s Take

Patients ask me about CBD and ageing more frequently than almost any other topic in cannabinoid medicine. This review is useful because it honestly maps where the science actually stands: nematode worms and fruit flies, not human beings. The mechanistic story is genuinely interesting. Autophagy induction and antioxidant pathway activation are legitimate targets in geroscience, and CBD appears to engage both in simple organisms. But the distance between a C. elegans lifespan extension and a meaningful human healthspan benefit is enormous, and this review does not pretend otherwise. The gap between what the lab shows and what a patient can act on remains vast.

In my practice, I do not recommend CBD as an anti-ageing intervention. When patients are already using CBD for a recognized indication such as chronic pain, anxiety, or sleep disruption, I ensure the product is third-party tested, the dose is rational, and we monitor for drug interactions, especially given the polypharmacy common in older adults. If someone asks whether CBD might also slow their ageing, I tell them the honest truth: the idea is biologically plausible but scientifically unproven in humans, and spending money on it for that purpose alone is not something I can endorse.

Clinical Perspective

This review sits very early in the research arc. It consolidates a body of preclinical work that is internally coherent but taxonomically distant from clinical medicine. The C. elegans data are the most developed, yet nematodes lack an endocannabinoid system homologous to the mammalian one, which complicates mechanistic extrapolation. The rodent CB1R knockout data are more directly relevant to human biology but address only the endogenous system, not exogenous cannabinoid supplementation. For clinicians fielding patient questions, the evidence supports intellectual interest but not patient-facing recommendations. There is currently no basis for advising any cannabinoid product as an ageing intervention in humans.

From a safety standpoint, clinicians should be aware that CBD inhibits cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, creating meaningful interaction risks with anticoagulants, statins, certain antihypertensives, and other medications commonly prescribed to the older adults most likely to seek anti-ageing products. Hepatotoxicity signals from high-dose CBD in the epilepsy literature further warrant caution. The review does not address these safety considerations, which is a notable omission given its ageing focus. One actionable step clinicians can take now is to proactively ask older patients about CBD use during medication reconciliation, regardless of the indication patients cite, and to counsel on interaction risks rather than on anti-ageing claims that evidence does not support.

Study at a Glance

Study Type

Narrative review (no systematic search protocol described)

Primary Model Organism

Caenorhabditis elegans (nematode)

Additional Models Covered

Drosophila, zebrafish, rodents, limited human molecular data

Key Cannabinoids Discussed

CBD, THC, CBG, CBN, CBC, cannabidiolic acid, cannabigerolic acid

Key Mechanisms Reviewed

Autophagy induction, antioxidative system activation, ECS receptor modulation, cellular senescence

Human Trial Evidence Included

None; only general quality-of-life reports cited

Journal

GeroScience (2024), vol. 46, pp. 5643-5661

Author Affiliation

Lambert Initiative for Cannabinoid Therapeutics, University of Sydney

Funding Source

Not specified in available data

Developmental Toxicity Coverage

Explicitly excluded from scope

What Kind of Evidence Is This

This is a narrative review, which occupies one of the lower tiers in the evidence hierarchy for informing clinical decisions. Unlike a systematic review or meta-analysis, it does not describe a reproducible search strategy, apply predefined inclusion and exclusion criteria, or formally assess the quality of the studies it synthesizes. The single most important inference constraint this design imposes is that the authors’ selection of studies may not be representative of the full literature, meaning positive findings could be overrepresented and null or negative results underrepresented without any mechanism to detect this bias.

How This Fits With the Broader Literature

The review’s emphasis on autophagy and oxidative stress as ageing-relevant pathways aligns with established geroscience frameworks, including work on rapamycin, caloric restriction, and senolytics. The C. elegans lifespan extension data for CBD are consistent with earlier reports from Pant and colleagues, and the ECS decline-with-age observations echo findings from Bilkei-Gorzo and colleagues, who demonstrated accelerated brain ageing in CB1R knockout mice. However, the broader cannabinoid-and-ageing literature remains thin and heavily weighted toward invertebrate models.

Notably absent from this review is any engagement with the negative or null findings that exist in the preclinical cannabinoid literature, or with the well-documented challenges of translating C. elegans lifespan hits to mammalian benefit. Many compounds that extend nematode lifespan have failed to do so in mice. This pattern of attrition should temper enthusiasm about the cannabinoid findings reviewed here, even when the mechanistic rationale is sound.

Common Misreadings

The most likely overinterpretation is treating this review as evidence that CBD slows human ageing. It does not provide or cite any such evidence. The studies it synthesizes were conducted overwhelmingly in C. elegans, an organism without a true endocannabinoid system, a circulatory system, or an immune system comparable to that of mammals. Extending nematode lifespan with a compound is a legitimate scientific finding, but it is many experimental steps removed from demonstrating a human healthspan benefit. Any claim that “research shows CBD fights ageing” based on this review would materially exceed what the data support.

Bottom Line

This narrative review consolidates a genuinely interesting preclinical story: CBD and the endocannabinoid system intersect with conserved ageing pathways in model organisms. But the evidence base is almost entirely invertebrate, with no controlled human data on lifespan or healthspan outcomes. For clinical practice, this work provides biological rationale for future research, not a foundation for recommending cannabinoids as anti-ageing interventions. The authors themselves are clear on this point, and clinicians should be equally clear with patients.

References

1. GeroScience (2024), vol. 46, pp. 5643-5661. Lambert Initiative for Cannabinoid Therapeutics, University of Sydney. Narrative review on cannabinoids and ageing.
2. Bilkei-Gorzo A, Albayram O, Drafber A, et al. A chronic low dose of delta-9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nature Medicine. 2017;23(6):782-787.
3. Pant A, Mishra V, Saikia SK, et al. Beta-caryophyllene modulates expression of stress response genes and mediates longevity in Caenorhabditis elegans. Experimental Gerontology. 2014;57:81-95.
4. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278.